Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label multicenter diagnostic skin prick study of ragweed pollen and dog dander prick solutions in allergic participants in China
CTR20263722Phase 3Active
- Sponsor
- Wolwo Biotech
- Start
- Oct 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of ambrosia artemisiifolia allergen extract and dog dander in immunoglobulin E-mediated hypersensitivity (3 arms), sponsored by Wolwo Biotech. Started Oct 2026; status: active.
02
Drugs
ambrosia artemisiifolia allergen extractdog dander
03
Conditions
immunoglobulin E-mediated hypersensitivity
Beyond the preview
Go deeper on CTR20263722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263722.